{"id":31647,"date":"2025-04-14T10:29:47","date_gmt":"2025-04-14T02:29:47","guid":{"rendered":"https:\/\/flcube.com\/?p=31647"},"modified":"2025-04-14T10:29:48","modified_gmt":"2025-04-14T02:29:48","slug":"cr-boya-gains-nmpa-approval-for-clinical-trials-of-subcutaneous-human-immunoglobulin","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31647","title":{"rendered":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin"},"content":{"rendered":"\n

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294<\/a>) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.<\/p>\n\n\n\n

Product Background and Market Context<\/strong>
Currently, similar products such as Hizentra, Cuvitru, and Xembify are available in overseas markets, having first secured marketing approval in the US, Holland, and the US in 2010, 2016, and 2019, respectively. However, foreign subcutaneous injection human immunoglobulin blood products are barred from domestic market approval in China, and no domestic manufacturers have been authorized to produce them. This leaves a significant gap in the market, with no approved subcutaneous injection human immunoglobulin products currently available in the country.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received…<\/p>\n","protected":false},"author":1,"featured_media":31648,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,511,1247],"class_list":["post-31647","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-cr-boya-biological-pharmacy","tag-she-300294"],"yoast_head":"\nCR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31647\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin\" \/>\n<meta property=\"og:description\" content=\"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31647\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T02:29:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-14T02:29:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin\",\"datePublished\":\"2025-04-14T02:29:47+00:00\",\"dateModified\":\"2025-04-14T02:29:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647\"},\"wordCount\":157,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1401-png.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CR Boya Biological Pharmacy\",\"SHE: 300294\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31647#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31647\",\"name\":\"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1401-png.webp\",\"datePublished\":\"2025-04-14T02:29:47+00:00\",\"dateModified\":\"2025-04-14T02:29:48+00:00\",\"description\":\"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31647\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1401-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/1401-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31647#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin - Insight, China's Pharmaceutical Industry","description":"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31647","og_locale":"en_US","og_type":"article","og_title":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin","og_description":"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.","og_url":"https:\/\/flcube.com\/?p=31647","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-14T02:29:47+00:00","article_modified_time":"2025-04-14T02:29:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31647#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31647"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin","datePublished":"2025-04-14T02:29:47+00:00","dateModified":"2025-04-14T02:29:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31647"},"wordCount":157,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31647#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","keywords":["Clinical trial approval \/ initiation","CR Boya Biological Pharmacy","SHE: 300294"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31647#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31647","url":"https:\/\/flcube.com\/?p=31647","name":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31647#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31647#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","datePublished":"2025-04-14T02:29:47+00:00","dateModified":"2025-04-14T02:29:48+00:00","description":"China-based CR Boya Biological Pharmacy Co. Ltd. (SHE: 300294) has announced that it has received clinical trial approval from the National Medical Products Administration of China (NMPA) for its human immunoglobulin for subcutaneous injection. The product is intended for the treatment of primary immunoglobulin deficiency, including conditions such as X-linked hypoimmunoglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subtype deficiency diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31647#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31647"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31647#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","width":1080,"height":608,"caption":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31647#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CR Boya Gains NMPA Approval for Clinical Trials of Subcutaneous Human Immunoglobulin"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/1401-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31647","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31647"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31647\/revisions"}],"predecessor-version":[{"id":31649,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31647\/revisions\/31649"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31648"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31647"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31647"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31647"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}